Triumph Capital Management Amgen Inc Transaction History

Triumph Capital Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 03, 2022	SELL	$219.27 - $242.57 $608,693 - $673,374	-2,776 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$198.88 - $227.6 $20,086 - $22,987	-101 Reduced 3.51%	2,776 $625,000
Q3 2021 Nov 16, 2021	BUY	$212.27 - $248.7 $610,700 - $715,509	2,877 New	2,877 $612,000
Q3 2021 Nov 15, 2021	SELL	$212.27 - $248.7 $543,835 - $637,169	-2,562 Closed	0 $0
Q2 2021 Jul 19, 2021	BUY	$233.58 - $259.14 $598,431 - $663,916	2,562 New	2,562 $627,000

3,055

409M

7.19M

6.26M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $171B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Triumph Capital Management, based on Form 13F filings with the SEC.

Stay updated on Triumph Capital Management with notifications on news.